BerGenBio - Invitation to conference call: interim update on Ph II clinical programme with selective AXL inhibitor bemcentinib being presented at ASCO

Bergen, Norway, 29 May 2018 – BerGenBio ASA (OSE:BGBIO) will host a conference call on Monday, 4 June at 8:30 AM CEST to present updated interim clinical and biomarker results from its ongoing Phase II development programme with selective AXL inhibitor bemcentinib. The data will be presented at the Annual American Society of Clinical Oncology (ASCO) meeting and at a reception hosted by BerGenBio (details below). 


Conference call details:

The call will be hosted by BerGenBio senior management and take place on:

Monday, 4 June 2018 at 8:30 AM CEST. 

To take part, please dial in 5-10 minutes prior to the scheduled start using below phone number and confirmation code 1068189:

Norway                      +47 2100 2608

United Kingdom       +44 (0) 330 336 9106

United States            +1 323 794 2594

A slide deck presentation to accompany the call will be made available at www.bergenbio.com in the Investors / Presentations section from 8:00 AM CEST on 4 June 2018.


Presentations to be made during the annual ASCO meeting:

Saturday 2 June, 6:00 – 8:00 PM CDT, Chicago School of the Art Institute, Chicago, IL

  • BerGenBio reception
    • New interim Phase II clinical trial data with bemcentinib and selected pre-clinical data to be discussed by BerGenBio principal investigators and invited key opinion leaders
    • For further details and to receive an invitation, please email to asco2018@bergenbio.com

Monday 4 June, 8:00 AM - 11:30 AM CDT, ASCO Annual Meeting, McCormick Center, Chicago, IL

  • Interim clinical data from clinical trial ref. BGBC008 – Poster Board: #292, Abstract 3078 
  • Interim clinical data from clinical trial ref. BGBC003 – Poster Board: #80, Abstract 7020
    • To be discussed at the Poster Discussion Session. 11:30 AM - 12:45 PM CDT
    • Biomarker study –  Poster Board: #385, Abstract 2559

Monday 4 June, 1:15 PM – 4:45 PM CDT, ASCO Annual Meeting, McCormick Center, Chicago, IL

  • Interim clinical data from clinical trial ref. BGBIL006 – Poster Board: #375, Abstract 9548

The posters presented at ASCO will be made available www.bergenbio.comin the Investors / Presentations section at the time of presentation.


-End-


About BerGenBio ASA 

BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors as a potential cornerstone of combination cancer therapy. The Company is a world leader in understanding the essential role of AXL kinase in mediating aggressive disease, including immune evasive, drug resistant, metastatic solid and haematological cancers.

BerGenBio’s lead product, bemcentinib (BGB324), is a selective, potent and orally bio-available small molecule AXL inhibitor in four Company sponsored Phase II clinical trials in major cancer indications, with read-outs anticipated during 2018. It is the only selective AXL inhibitor in clinical development.

The Company sponsored clinical trials are:

  • Bemcentinib with TARCEVA® (erlotinib) in advanced EGFR mutation driven non-small cell lung cancer (NSCLC)
  • Bemcentinib with KEYTRUDA in advanced adenocarcinoma of the lung, and
  • Bemcentinib with KEYTRUDA in triple-negative breast cancer (TNBC).
  • Bemcentinib as a single agent and combination therapy in acute myeloid leukaemia (AML) / myeloid dysplastic syndrome (MDS)

The clinical trials combining bemcentinib with KEYTRUDA in adenocarcinoma of the lung and TNBC are conducted in collaboration with Merck & Co., Inc. (Kenilworth, NJ, USA), through a subsidiary.

In addition, a number of investigator-sponsored trials are underway, including a trial to investigate bemcentinib with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial combining bemcentinib with docetaxel in advanced NSCLC.

BerGenBio is simultaneously developing a companion diagnostic test to identify patient subpopulations most likely to benefit from treatment with bemcentinib. This will facilitate more efficient registration trials and support a precision medicine based commercialization strategy.

The Company is also developing a diversified pre-clinical pipeline of drug candidates, including BGB149, an anti-AXL monoclonal antibody.

For further information, please visit: www.bergenbio.com 

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a registered trademark of Novartis International AG and MEKINIST® is a registered trademark of GSK plc.


Contacts  

Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

Media Relations in Norway

Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891

International Media Relations

David Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogerson
bergenbio@citigatedewerogerson.com
+44 207 638 9571


Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Tags:

About Us

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.

Subscribe